title: Pre-transplant 18FDG-PET predicts outcome in lymphoma patients treated with high-dose sequential chemotherapy followed by autologous stem cell transplantation.
abstract: We evaluated the prognostic role of 18FDG-PET performed before ASCT in patients affected by lymphoma who underwent high-dose chemotherapy followed by ASCT as first-line treatment for high-risk disease or as second-line or more for relapsed or refractory disease. We retrospectively analyzed 53 consecutive patients, 14 with Hodgkin Lymphoma (HL) and 39 with non-Hodgkin Lymphoma (NHL), treated between February 1999 and October 2006 at our institution, who had a pre-ASCT FDG-PET (pPET) evaluation. Median age was 45 years (range: 18-69). After a median follow-up of 31 months (range: 8-91), 7 out of 16 pPET+ patients and 10 out of 37 pPET- patients experienced lymphoma relapse. The 5-year OS is 90% and 55% (p = 0.01) in patients with negative and positive pPET, respectively. In conclusion, a positive pPET indicates a poorer outcome after ASCT with respect to a negative pPET; this subset of patients should be considered candidate to more intensive or investigational approaches.
authors.affiliation: Hematology and BMT Unit, Department of Oncology, San Raffaele Scientific Institute, Milano, Italy. crocchiolo.roberto@hsr.it
authors.forename: Roberto
authors.initials: R
authors.lastname: Crocchiolo
authors.forename: Carla
authors.initials: C
authors.lastname: Canevari
authors.forename: Andrea
authors.initials: A
authors.lastname: Assanelli
authors.forename: Francesca
authors.initials: F
authors.lastname: Lunghi
authors.forename: Michela
authors.initials: M
authors.lastname: Tassara
authors.forename: Maria Lupo
authors.initials: ML
authors.lastname: Stanghellini
authors.forename: Daniela
authors.initials: D
authors.lastname: Clerici
authors.forename: Claudio
authors.initials: C
authors.lastname: Landoni
authors.forename: Paolo
authors.initials: P
authors.lastname: Servida
authors.forename: Massimo
authors.initials: M
authors.lastname: Bernardi
authors.forename: Jacopo
authors.initials: J
authors.lastname: Peccatori
authors.forename: Andres
authors.initials: A
authors.lastname: Ferreri
authors.forename: Luigi
authors.initials: L
authors.lastname: Gianolli
authors.forename: Claudio
authors.initials: C
authors.lastname: Bordignon
authors.forename: Federico
authors.initials: F
authors.lastname: Caligaris-Cappio
authors.forename: Fabio
authors.initials: F
authors.lastname: Ciceri
authors.forename: Ferruccio
authors.initials: F
authors.lastname: Fazio
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D019788:Fluorodeoxyglucose F18; D018380:Hematopoietic Stem Cell Transplantation / Q000379:methods*; D006801:Humans; D008228:Lymphoma, Non-Hodgkin / Q000175:diagnosis* / Q000401:mortality / Q000628:therapy*; D008875:Middle Aged; D049268:Positron-Emission Tomography / Q000379:methods*; D011300:Preoperative Care; D011379:Prognosis; D012008:Recurrence; D012189:Retrospective Studies; D015996:Survival Rate; D014182:Transplantation, Autologous
chemical_list: D019788:Fluorodeoxyglucose F18